Format

Send to

Choose Destination
Orphanet J Rare Dis. 2017 Jul 19;12(1):132. doi: 10.1186/s13023-017-0684-3.

Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders.

Author information

1
Metabolic Genetics and Nutrition Program, Emory University, Atlanta, GA, USA. yadadev@emory.edu.
2
Department of Human Genetics, Metabolic Genetics and Nutrition Program, Emory University, 2165 North Decatur Road, Decatur, GA, 30033, USA. yadadev@emory.edu.
3
Department of Individual, Family and Community Education, University of New Mexico, Albuquerque, NM, USA.
4
Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.
5
Metabolic Genetics and Nutrition Program, Emory University, Atlanta, GA, USA.

Abstract

BACKGROUND:

Newborn Screening Connect (NBS Connect) is a web-based self-reported patient registry and resource for individuals and families affected by disorders included in the newborn screening panel. NBS Connect was launched in 2012 by Emory University after years of planning and grassroots work by professionals, consumers, and industry. Individuals with phenylketonuria (PKU), maple syrup urine disease (MSUD) or tyrosinemia (TYR) have been recruited through distribution of outreach materials, presentations at parent organization meetings and direct recruitment at clinic appointments. Participants complete online profiles generating data on diagnosis, treatment, symptoms, outcomes, barriers to care, and quality of life. Resources such as education materials, information on the latest research and clinical trials, recipes, interactive health tracking systems, and professional support tools are described. In addition, to examine the ability of NBS Connect to generate data that guides hypothesis-driven research, data pertaining to age at diagnosis, bone health, and skin conditions in individuals with PKU were assessed. The objective of this paper is to describe the development of NBS Connect and highlight its data, resources and research contributions.

RESULTS:

In September 2016, NBS Connect had 442 registered participants: 314 (71%) individuals with PKU, 68 (15%) with MSUD, 20 (5%) with TYR, and 40 (9%) with other disorders on the NBS panel. Age at diagnosis was less than 4 weeks in 285 (89%) of 319 respondents to this question and between 1 month and 14 years in 29 (9%) individuals. Of 216 respondents with PKU, 33 (15%) had a DXA scan in the past year. Of 217 respondents with PKU, 99 (46%) reported at least one skin condition.

CONCLUSIONS:

NBS Connect was built and refined with feedback from all stakeholders, including individuals with inherited metabolic disorders. Based on patient-reported data, future studies can be initiated to test hypotheses such as the relationship between PKU and skin conditions. Patient registries like NBS Connect can inform hypothesis-driven research, contributing to knowledge generation and following the current trend in moving from traditional medicine towards evidence-based practice. NBS Connect will help clinicians understand long-term outcomes of rare disorders, contributing to better patient care and quality of life.

KEYWORDS:

Maple syrup urine disease; Metabolic disorders; NBS Connect; Newborn screening; Patient registry; Phenylketonuria; Tyrosinemia

PMID:
28724394
PMCID:
PMC5517813
DOI:
10.1186/s13023-017-0684-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center